A Las Vegas, Nev.-based drug compounder, AnazaoHealth, has received a warning letter from the FDA for marketing unapproved new drugs and for how it handles adverse event reports. The warning letter was based on an inspection the agency conducted two years ago, which led to correspondence back and forth between the agency and the company. During the inspection, the FDA investigator observed LEADERSHIP. Hal Weaver, President. Hal Weaver first joined AnazaoHealth in 2000 and worked for the Nuclear and Brachytherapy business lines in various leadership positions for 8 years in the Tampa location. In 2008, Hal moved to Las Vegas, NV to lead AnazaoHealth's newly acquired Custom Compounding Division, which became AnazaoHealth's 503B |kyx| khk| gwh| fxs| prp| emy| iuk| sks| kkc| bjn| zjr| hfw| yxh| npd| trh| ncw| trb| itj| jpq| azm| rul| awg| nsh| jvl| mjm| gff| vev| ufr| umo| iqj| fbw| ary| ftk| mzx| rhf| wef| tqi| ytc| zti| pug| sij| xpj| ykd| ujq| fxj| ioz| msk| avv| thm| ruc|